Indivior Pharmaceuticals, Inc. (INDV) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $155.00M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-28.00M; Retained Earnings (Accumulated Deficit)USD $-334.00M.
- 2026-03-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $165.00M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-29.00M; Retained Earnings (Accumulated Deficit)USD $-280.00M.
- 2025-12-31: Common Stock, Value, IssuedUSD $62.00M; Additional Paid in CapitalUSD $112.00M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-30.00M; Retained Earnings (Accumulated Deficit)USD $-243.00M.
- 2025-09-30: Common Stock, Value, IssuedUSD $62.00M; Additional Paid in CapitalUSD $109.00M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-32.00M; Retained Earnings (Accumulated Deficit)USD $-346.00M.
Indivior Pharmaceuticals, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock Acquired, Average Cost Per Share USD/shares | Retained Earnings USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $155.00M | $-28.00M | $-334.00M | $-208.00M | 3 month · $11.00M | (m) | (m) |
| 2026-03-31 | $0.00 | $165.00M | $-29.00M | $-280.00M | $-144.00M | 3 month · $9.00M | 3 month · 31.45 | (m) |
| 2025-12-31 | $62.00M | $112.00M | $-30.00M | $-243.00M | $-98.00M | 12 month · $26.00M | (m) | (m) |
| 2025-09-30 | $62.00M | $109.00M | $-32.00M | $-346.00M | $-207.00M | 3 month · $6.00M | (m) | (m) |
| 2025-06-30 | $62.00M | $101.00M | $-33.00M | $-388.00M | $-257.00M | 3 month · $8.00M | (m) | (m) |
| 2025-03-31 | $62.00M | $93.00M | $-35.00M | $-406.00M | $-285.00M | 3 month · $6.00M | (m) | (m) |
| 2024-12-31 | $62.00M | $90.00M | $-36.00M | $-443.00M | $-337.00M | 12 month · $24.00M | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | $-310.00M | 3 month · $6.00M | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | $-281.00M | 3 month · $6.00M | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | $-161.00M | 3 month · $6.00M | (m) | (m) |
| 2023-12-31 | $68.00M | $88.00M | $-30.00M | $-288.00M | $-184.00M | 12 month · $21.00M | (m) | $1.24B |
| 2022-12-31 | (m) | (m) | (m) | (m) | $-15.00M | 12 month · $16.00M | (m) | $1.30B |
| 2021-12-31 | (m) | (m) | (m) | (m) | $121.00M | (m) | (m) | $1.44B |
| 2014-12-23 | (m) | (m) | (m) | $-1.29B | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |